

CITATION REPORT

List of articles citing

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

DOI: [10.1200/jco.2009.23.3734](https://doi.org/10.1200/jco.2009.23.3734)

Journal of Clinical Oncology, 2009, 27, 5538-46.

Source: <https://exaly.com/paper-pdf/45469396/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
896	Endocrine-responsive breast cancer: a 28-year Odyssey. 2011 , 5, 237		
895	Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. 2008 , 108, c278-83		47
894	Cardiac troponin T and advanced glycation end-products in hemodialysis patients. 2008 , 28, 701-6		2
893	Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer. 2009 , 4, 373-378		5
892	How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5492-4	2.2	16
891	Overcoming endocrine resistance in breast cancer. 2010 , 10, 519-28		7
890	[Biomarkers of endocrine therapy-resistance in breast cancers]. 2010 , 97, 951-63		1
889	[Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)]. 2010 , 136, 175-84		
888	HER2-Antikörper plus Hormontherapie. 2010 , 13, 37-39		
887	Treatment strategy for HER2-positive breast cancer. 2010 , 15, 335-40		20
886	L'association hormonothérapie-thérapie ciblée dans le cancer du sein. 2010 , 12, 422-431		
885	Triple-negative breast cancer. 2010 , 160, 174-81		23
884	Endocrine Therapy for Metastatic Disease: Reversing Resistance. 2010 , 2, 114-119		
883	Cancer du sein avancé ou métastatique HER2+: évolution de la prise en charge. 2010 , 4, 16-18		0
882	Mechanisms of resistance to hormonal treatment in breast cancer. 2010 , 12, 246-52		12
881	Receptor discordance: does it mean anything?. 2010 , 10, 419-20		2
880	Targeting endocrine resistance: is there a role for mTOR inhibition?. 2010 , 10 Suppl 3, S79-85		17

879	Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells. 2010 , 101, 1661-9		9
878	Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. 2010 , 29, 6071-83		53
877	Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. <i>Cancer Management and Research</i> , 2010 , 13	3.6	2
876	Assessment of the efficacy and safety of lapatinib in combination with capecitabine in patients with metastatic HER2-positive breast cancer treated in Centrum Onkologii Ziemi Lubelskiej. 2010 , 2, 79-86		1
875	2009 Publications of the Baylor Health Care System Medical and Scientific Staff. 2010 , 23, 202-219		
874	Lapatinib: new opportunities for management of breast cancer. 2010 , 2, 79-91		7
873	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 2010 , 2, 93-109		6
872	Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. 2010 , 107, 85-91		62
871	A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. 2010 , 79, 129-35		32
870	Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1904-14	12.9	141
869	New strategies in estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1979-87	12.9	152
868	Tyrosine kinase inhibitors. 2010 , 10, 462-83		33
867	Chemotherapy with or without trastuzumab. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii112-9	10.3	7
866	Cancer du sein en situation mēastatique. 2010 ,		
865	Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. <i>Clinical Cancer Research</i> , 2010 , 16, 1486-97	12.9	76
864	Simultaneous targeting of estrogen receptor and HER2 in breast cancer. 2010 , 10, 1255-63		12
863	Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. 2010 , 15, 924-34		227
862	Lapatinib and breast cancer: current indications and outlook for the future. 2010 , 10, 1171-82		21

861	Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. 2010 , 15, 122-9		147
860	Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e258-e259	2.2	2
859	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v15-9	10.3	92
858	Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges. 2010 , 5, 1-2		2
857	Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer. 2010 , 5, 13-15		8
856	The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. 2010 , 5, 134-141		5
855	Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer. 2010 , 5, 345-351		7
854	Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. 2010 , 40, 999-1013		14
853	Does lapatinib work against HER2-negative breast cancers?. <i>Clinical Cancer Research</i> , 2010 , 16, 1355-7	12.9	15
852	Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directions. 2010 , 10, 3-18		1
851	Past, present and future of targeted therapy in solid tumors. 2010 , 10, 433-61		26
850	Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. 2010 , 15, 944-53		23
849	Biological considerations and clinical applications of new HER2-targeted agents. 2010 , 10, 1497-509		8
848	Present and future evolution of advanced breast cancer therapy. 2010 , 12 Suppl 2, S1		40
847	Molecular basis for therapy resistance. 2010 , 4, 284-300		36
846	Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. 2010 , 7, 139-47		132
845	Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. 2010 , 12, R96		76
844	Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. 2010 , 70, 1411-22		9

843	Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. 2010 , 10, 188-95		32
842	Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. 2010 , 10, 421-39		3
841	Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. 2010 , 10 Suppl 2, S30-40		
840	Nanoparticle albumin-bound (nab [®])-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. 2010 , 8, 1-10		86
839	Emerging targeted therapies for breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3366-79	2.2	148
838	Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. 2010 , 36, 410-5		25
837	EGFR signaling in breast cancer: bad to the bone. 2010 , 21, 951-60		109
836	Lapatinib in breast cancer: clinical experiences and future perspectives. 2010 , 36 Suppl 3, S72-9		18
835	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. 2010 , 26, 767-75		13
834	Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. 2011 , 10, 518-30		68
833	Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. 2011 , 4, 293-300		19
832	Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?. 2011 , 7, 333-44		13
831	Deconstructing the molecular portraits of breast cancer. 2011 , 5, 5-23		841
830	Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. 2011 , 27, 2245-52		6
829	Recent developments in treatment stratification for metastatic breast cancer. 2011 , 71, 2099-113		10
828	Cancer stem cells and side population cells in breast cancer and metastasis. <i>Cancers</i> , 2011 , 3, 2106-30	6.6	40
827	Cancer Stem Cells in Solid Tumors. 2011 ,		6
826	HER2 and hormone receptor-positive breast cancer--blocking the right target. 2011 , 8, 307-11		24

825	New and translational perspectives of oestrogen deprivation in breast cancer. 2011 , 340, 137-41	9
824	Aromatase, aromatase inhibitors, and breast cancer. 2011 , 125, 13-22	196
823	Aromatase inhibitors and xenograft studies. 2011 , 76, 730-5	13
822	The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. 2011 , 76, 807-11	2
821	The role of chemotherapy and targeted agents in patients with metastatic breast cancer. 2011 , 47 Suppl 3, S38-47	28
820	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. 2011 , 13, 224	302
819	Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal women. 2011 , 8, 343-352	1
818	Targeted therapies for breast cancer. 2011 , 121, 3797-803	248
817	Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. 2011 , 3, CMT.S3783	7
816	Oral chemotherapeutic agents in current use. 2011 , 54, 1191	4
815	Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. 2011 , 3, 139-50	1
814	Combining molecular targeted therapies: clinical experience. 2011 , 22, 701-10	7
813	HER2-overexpressing breast cancer: time for the cure with less chemotherapy?. 2011 , 23, 547-58	15
812	Les cancers du sein HER2 : que devons-nous retenir dans notre pratique clinique quotidienne ?. 2011 , 98, 154-163	4
811	Invasive breast cancer. 2011 , 9, 136-222	99
810	Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. 2011 , 30, 3084-95	48
809	Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?. 2011 , 104, 1059-66	60
808	Beyond trastuzumab: new treatment options for HER2-positive breast cancer. 2011 , 20 Suppl 3, S20-7	46

807	Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 2011 , 20 Suppl 3, S42-9	63
806	Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?. 2011 , 20 Suppl 3, S158-61	12
805	The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium. 2011 , 11, 15-9	1
804	Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. 2011 , 80, 433-49	41
803	Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. 2011 , 11, 146-52	29
802	Mechanisms of endocrine resistance in breast cancer. 2011 , 62, 233-47	793
801	HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. 2011 , 129, 659-74	92
800	A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. 2011 , 129, 819-27	28
799	Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions. 2011 , 63, 67-80	8
798	Place des thérapies ciblées chez la patiente âgée atteinte de cancer du sein. 2011 , 13, 97-101	
797	Cancer du sein méta-analyse en première ligne. 2011 , 13, 758-777	1
796	SEOM clinical guidelines for using molecular markers in clinical practice. 2011 , 13, 587-91	
795	Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates. 2011 , 5, 119-128	1
794	Individualization of treatment strategies. 2011 , 28 Suppl 6, 19-38	5
793	Management of patients with metastatic breast cancer. 2011 , 28 Suppl 6, 50-65	13
792	A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. 2011 , 28, 603-14	5
791	An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. 2011 , 28, 1045-58	17
790	Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif. 2011 , 3, 128-140	

789	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. 2011 , 3, 24-33		
788	Incorporating Agents that Target HER2 in the Neoadjuvant Setting. 2011 , 3, 190-196		
787	Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance. 2011 , 3, 181-189		
786	Breast cancer stem cells and their role in resistance to endocrine therapy. 2011 , 2, 91-103		46
785	Hematologic toxicities of small molecule tyrosine kinase inhibitors. 2011 , 6, 203-15		11
784	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. <i>BMC Cancer</i> , 2011 , 11, 248	4.8	110
783	Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. 2011 , 103, 574-86		18
782	Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making?. 2011 , 77, 87-99		1
781	Emerging drugs in metastatic breast cancer: an update. 2011 , 16, 647-67		7
780	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. 2011 , 12, 549-65		7
779	[Individualized treatment of breast cancer]. 2011 , 136, 486-91		2
778	Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4452-61	2.2	302
777	Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, C19-24	5.7	99
776	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. <i>Journal of Clinical Oncology</i> , 2011 , 29, 166-73	2.2	196
775	Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. 2011 , 4, 1181-9		50
774	Targeting the HER/EGFR/ErbB family to prevent breast cancer. 2011 , 4, 1149-57		73
773	Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. <i>Annals of Oncology</i> , 2011 , 22, 17-23	10.3	21
772	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011 , 22 Suppl 6, vi25-30	10.3	75

771	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. <i>Clinical Cancer Research</i> , 2011 , 17, 1147-59	12.9	142
770	Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: a bumpy start with an uncertain future. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3846-8	2.2	3
769	Current targeted therapies in breast cancer: clinical applications in the elderly woman. 2011 , 16, 1144-53		9
768	Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. 2011 , 5, 67-77		6
767	Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. 2011 , 5, 97-103		2
766	Handbook of Metastatic Breast Cancer. 2011 ,		
765	Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. <i>Clinical Cancer Research</i> , 2011 , 17, 5559-61	12.9	28
764	When are "positive" clinical trials in oncology truly positive?. 2011 , 103, 16-20		83
763	Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?. 2011 , 6, 35-41		2
762	Lapatinib in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer: profile report. 2011 , 25, 53-4		1
761	Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. <i>Clinical Cancer Research</i> , 2011 , 17, 4208-13	12.9	24
760	The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. <i>Annals of Oncology</i> , 2011 , 22, 1308-1317	10.3	55
759	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 667-73	2.2	223
758	Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. 2011 , 24, 367-74		41
757	Lapatinib for breast cancer: a review of the current literature. 2011 , 10, 109-21		20
756	Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima. 2011 , 41, 924-30		
755	The sequential use of endocrine treatment for advanced breast cancer: where are we?. <i>Annals of Oncology</i> , 2012 , 23, 1378-86	10.3	51
754	Predictive Biomarkers in Early Drug Development Challenges and Opportunities. <i>Annals of Oncology</i> , 2012 , 23, xi10	10.3	

753	Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. 2012 , 17, 631-44		25
752	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 1455-64	10.3	8
751	Lapatinib for advanced or metastatic breast cancer. 2012 , 17, 536-42		41
750	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii11-9	10.3	356
749	Reversing hormone resistance: have we found the golden key?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2707-9	2.2	24
748	Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1897-900	2.2	9
747	Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. 2012 , 13, 1269-75		26
746	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 2012 , 13, 2143-56		6
745	Progress against solid tumors in danger: the metastatic breast cancer example. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3444-7	2.2	17
744	Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. 2012 , 106, 6-13		71
743	Cancer du sein. 2012 ,		
742	Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. 2012 , 4, 127-37		22
741	Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. 2012 , 11, 1978-87		60
740	Toward individualized breast cancer therapy: translating biological concepts to the bedside. 2012 , 17, 577-84		14
739	Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. 2012 , 9, 143-163		44
738	Aromatase inhibitors and breast cancer. 2012 , 9, 119-26		2
737	Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. 2012 , 4, 173-82		8
736	The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. 2012 , 2012, 743193		222

735	Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. 2012 , 6, 191-207		7
734	Efficacy and tolerability of lapatinib in the management of breast cancer. 2012 , 6, 67-77		15
733	Lapatinib and renal cell carcinoma. 2012 , 21, 1727-32		3
732	US Food and Drug Administration approval overview in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1705-11	2.2	44
731	Recent advances in novel targeted therapies for HER2-positive breast cancer. 2012 , 23, 765-76		52
730	Endocrine resistance in advanced breast cancer: current evidence and future directions. 2012 , 1, 305-314		1
729	Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. 2012 , 28, 2211-6		7
728	[Targeted based therapies in metastatic breast cancer: future evolution]. 2012 , 67, 491-503		
727	Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach. 2012 , 9, 287-299		1
726	Oral Chemotherapeutic Agents. 2012 , 1		1
725	Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. 2012 , 40, 1858-64		21
724	HER2-positive metastatic breast cancer: a double-edged sword. 2012 , 1, 181-184		
723	Targeted therapies in breast cancer. 2012 , 142, w13550		9
722	The paradigm of personalized therapy in oncology. 2012 , 16 Suppl 1, S7-16		16
721	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012 , 52, 549-73		82
720	[Targeted therapy and breast cancer: state of the art]. 2012 , 60, 254-63		2
719	Simultaneous Systematic Approach to Enable Predictive, Preventive and Personalized Medicine â Women Healthcare as a Case Study. 2012 , 313-331		2
718	Efficacy and pharmacogenomic biomarkers in breast cancer. 2012 , 6, 211-21		1

717	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). 2012 , 13, e148-60	418
716	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. 2012 , 13, 135-44	363
715	Understanding the mechanisms of aromatase inhibitor resistance. 2012 , 14, 201	64
714	BOLERO-2 - will this change practice in advanced breast cancer?. 2012 , 14, 311	8
713	Targeted therapies in breast cancer: are heart and vessels also being targeted?. 2012 , 14, 209	21
712	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. 2012 , 14, R46	35
711	Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. 2012 , 14, R95	80
710	Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. 2012 , 135, 39-48	70
709	Role of epidermal growth factor receptor in breast cancer. 2012 , 136, 331-45	371
708	Breast cancer therapies and cardiomyopathy. 2012 , 96, 1001-19	9
707	Treatment of HER2-positive breast cancer: current status and future perspectives. 2011 , 9, 16-32	606
706	The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. 2012 , 135, 681-92	39
705	Why RECIST works and why it should stay--counterpoint. 2012 , 72, 5151-7; discussion 5158	20
704	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. 2012 , 38, 303-10	24
703	Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. 2012 , 38, 505-14	47
702	New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?. 2012 , 38, 494-504	37
701	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. <i>BMC Cancer</i> , 2012 , 12, 322	4.8 14
700	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. 2012 , 12, 1391-405	16

699	Targeting the EGFR signaling pathway in cancer therapy. 2012 , 16, 15-31	512
698	Targeting the subtypes of breast cancer: rethinking investigational drugs. 2012 , 21, 191-204	1
697	Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). 2012 , 28, 1263-79	21
696	Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. 2012 , 13, 766-7	4
695	Target therapy in elderly breast cancer patients. 2012 , 83, 422-31	5
694	Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?. 2012 , 84, 243-51	45
693	HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies. 2012 , 9, e55-e60	1
692	Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity. 2012 , 73, 288-94	17
691	Omics and therapy - a basis for precision medicine. 2012 , 6, 128-39	30
690	Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. 2012 , 1, 217-233	1
689	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. 2012 , 9, 529-41	57
688	Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. 2012 , 29, 3232-9	12
687	Prevention and management of major side effects of targeted agents in breast cancer. 2012 , 84 Suppl 1, e79-85	10
686	Novel targeted agents for the treatment of advanced breast cancer. 2012 , 4, 893-914	9
685	BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. 2012 , 107, 947-55	55
684	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. 2012 , 98, 33-38	4
683	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. 2012 , 99, E18-25	2
682	Oncology Phase I Trials at Shizuoka Cancer Center. <i>Annals of Oncology</i> , 2012 , 23, xi10	10.3

681	HER2-Neu in Breast Cancer: History and Future Directions. <i>Annals of Oncology</i> , 2012 , 23, xi10-xi11	10.3
680	HER2 as a Therapeutic Target in Ovarian Cancer. 2012 ,	1
679	Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. 2012 , 6, 56-63	5
678	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. 2012 , 4, 35-51	7
677	Neratinib (HKI-272) in the treatment of breast cancer. 2012 , 8, 671-81	23
676	The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3012-9	2.2 125
675	Current and emerging targeted therapies for metastatic breast cancer. 2012 , 118, 3014-25	34
674	Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. 2012 , 118, 4936-43	21
673	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. 2012 , 134, 583-93	28
672	Chemotherapy-resistant metastatic breast cancer. 2012 , 13, 263-75	72
671	Evolving strategies to overcome endocrine resistance in breast cancer. 2012 , 5, 105-109	
670	What's new in metastatic breast cancer?. 2012 , 5, 110-115	
669	Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?. 2012 , 19, 212-7	4
668	Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. 2012 , 133, 595-606	63
667	Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. 2012 , 133, 703-11	46
666	Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. 2012 , 12, 19-29	26
665	The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. 2012 , 12, 157-66	6
664	UK guidance document: treatment of metastatic breast cancer. 2012 , 24, 169-76	8

663	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. 2012 , 21, 27-33		160
662	1st International consensus guidelines for advanced breast cancer (ABC 1). 2012 , 21, 242-52		258
661	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 2012 , 118, 17-26		49
660	Optimizing Endocrine Therapy for Metastatic Breast Cancer. 2012 , 4, 30-38		3
659	Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. 2012 , 4, 66-74		2
658	Dual HER2-targeted approaches in HER2-positive breast cancer. 2012 , 131, 371-83		45
657	Cancer du sein métastatique surexprimant HER2 : évolutions des thérapeutiques. 2012 , 14, 37-40		
656	HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. 2013 , 15, R11		46
655	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. 2013 , 34, 8690-707	323	
654	The Future of Chemotherapy in the Era of Personalized Medicine. 2013 , 5, 57-68		2
653	Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2013 , 13, 241	4.8	20
652	Fool's gold, lost treasures, and the randomized clinical trial. <i>BMC Cancer</i> , 2013 , 13, 193	4.8	36
651	Mehrfach zielgerichtete Therapie beim Mammakarzinom. 2013 , 46, 267-272		
650	Luminal breast cancer: from biology to treatment. 2013 , 10, 494-506		123
649	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. 2013 , 21, 3243-54		37
648	Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. 2013 , 21, 2341-9		37
647	Metastasiertes Mammakarzinom. <i>Onkologe</i> , 2013 , 19, 487-493		0.1
646	Duration of trastuzumab for HER2-positive breast cancer. 2013 , 14, 678-9		3

645	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. 2013 , 37, 110-44		40
644	Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. 2013 , 22, 823-40		22
643	Inflammatory Breast Cancer. 2013 ,		
642	Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. <i>Clinical Cancer Research</i> , 2013 , 19, 2646-56	12.9	15
641	¹⁸ F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. 2013 , 54, 1862-8		105
640	A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. 2013 , 39, 457-65		41
639	[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. 2013 , 42, 1461-8		5
638	Treating the HER2 pathway in early and advanced breast cancer. 2013 , 27, 751-65, viii		14
637	Endocrine therapy: is the first generation of targeted drugs the last?. 2013 , 274, 144-52		34
636	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. 2013 , 15, R92		248
635	Résistance aux traitements du cancer du sein (RPC 2013). 2013 , 15, 688-692		1
634	New Approaches for Hormone-Receptor Positive Metastatic Breast Cancer. 2013 , 5, 309-320		
633	Biomarkers of Therapeutic Resistance in Breast Cancer. 2013 , 5, 275-283		
632	Endocrine therapy for advanced/metastatic breast cancer. 2013 , 27, 715-36, viii		32
631	Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. <i>International Journal of Molecular Sciences</i> , 2012 , 14, 108-45	6.3	166
630	HER story: the next chapter in HER-2-directed therapy for advanced breast cancer. 2013 , 18, 1153-66		14
629	Cardiotoxicity of novel HER2-targeted therapies. 2013 , 29, 1015-24		61
628	Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. <i>Annals of Oncology</i> , 2013 , 24, 283-291	10.3	39

627	Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. 2013 , 137, 1-12	22
626	A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. 2013 , 137, 755-66	38
625	New developments and future directions in systemic therapy. 2013 , 25, 117-26	9
624	Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. 2013 , 49, 989-98	12
623	Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. 2013 , 22, 142-149	10
622	Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. 2013 , 205, 212-21	81
621	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. 2013 , 14, 88-96	112
620	Lapatinib in early breast cancer--questions to be resolved. 2013 , 14, 11-2	40
619	A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. 2013 , 39, 720-7	39
618	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. 2013 , 14, 541-54	33
617	Current approaches and future directions in the treatment of HER2-positive breast cancer. 2013 , 39, 219-29	98
616	Targeted therapies of metastatic breast cancer: relationships with cancer stem cells. 2013 , 67, 543-55	11
615	Changing concepts of hormone receptor-positive advanced breast cancer therapy. 2013 , 13, 159-66	22
614	Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06. 2013 , 8, 137-43	7
613	The evolving landscape of protein kinases in breast cancer: clinical implications. 2013 , 39, 68-76	19
612	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. 2013 , 22, 1-12	77
611	RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. 2013 , 138, 427-35	15
610	Antibody-Drug Conjugates and Immunotoxins. 2013 ,	4

609	Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 2013 , 8, 256-62		74
608	Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. 2013 , 8, 67-70		18
607	Health economic aspects of breast cancer treatment: the compulsory health insurances' view. 2013 , 8, 23-8		2
606	Palliative Therapie beim Mammakarzinom. 2013 , 7, 407-422		2
605	Phase III clinical trials that integrate treatment and biomarker evaluation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3158-61	2.2	38
604	Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2. 2013 , 2, 529-535		1
603	[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]. 2013 , 100, 1295-310		3
602	Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. <i>Annals of Oncology</i> , 2013 , 24, 2492-2500	10.3	39
601	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. <i>Annals of Oncology</i> , 2013 , 24, 2715-24	10.3	84
600	First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. 2013 , 18, 501-10		51
599	Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. 2013 , 17, E58-62		1
598	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). <i>Annals of Oncology</i> , 2013 , 24, 924-30	10.3	11
597	Advances in the treatment of luminal breast cancer. 2013 , 25, 49-54		13
596	Why your preferred targeted drugs may become unaffordable. 2013 , 73, 5849-51		7
595	Alopecia with endocrine therapies in patients with cancer. 2013 , 18, 1126-34		35
594	Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1703-6	2.2	21
593	Trastuzumab: qui bono?. 2013 , 105, 1772-5		3
592	Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2128-35	2.2	299

591	Phase III trials of targeted anticancer therapies: redesigning the concept. <i>Clinical Cancer Research</i> , 2013 , 19, 4931-40	12.9	17
590	GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. 2013 , 73, 3783-95		74
589	Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. 2013 , 21, 420-5		1
588	Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. <i>Endocrine-Related Cancer</i> , 2013 , 20, R183-201	5.7	77
587	New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. 2013 , 9, 27-36		16
586	Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. 2013 , 2, 336-41		18
585	Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. 2013 , 83, 857-69		31
584	Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. 2013 , 9, 319-26		47
583	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 2013 , 32, 5315-30		38
582	Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1947-53	2.2	113
581	Lapatinib inhibits the activation of NF- κ B through reducing phosphorylation of I κ B in breast cancer cells. 2013 , 29, 812-8		11
580	Targeted therapy in HER2-positive breast cancer. 2013 , 1, 499-505		39
579	HER-2 as a Prognostic and Predictive Biomarker in Cancer. 2013 , 77-120		
578	Hormone Receptors and Endocrine Therapy in Breast Cancer. 2013 , 121-153		
577	ADVANCES WITH AROMATASE INHIBITORS. 2013 , 201-227		
576	Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer. 2013 , 8, 429-37		8
575	Targeting HER receptors in cancer. 2013 , 19, 808-17		32
574	Network-based approaches for anticancer therapy (Review). 2013 , 43, 1737-44		11

573	Lapatinib and Letrozole as First-Line Therapy for Metastatic Breast Cancer: Case Report of Bone Metastasis 18 Years Later. 2013 , 99, e264-e268	
572	Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. 2013 , 8, e74618	14
571	Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis. 2013 , 8, 69-78	9
570	Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. 2013 , 20, e371-87	17
569	"Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?. 2013 , 3, 124-43	14
568	Ten years of progress against breast cancer: a partnership of basic and clinical/translational science. 2013 , 11, 132-6	
567	Treating breast cancer in the 21st century: emerging biological therapies. 2013 , 4, 117-32	116
566	Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. 2014 , 1, GRHTA.5000182	8
565	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. 2014 , 5, 990-1001	73
564	Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. 2014 , 5, 440-54	11
563	Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. 2014 , 14, 1229-42	6
562	Biologisch stratifizierte Therapie. 2014 , 17, 46-52	
561	Managing breast cancers with low estrogen receptor and HER2 by drugging both. <i>Clinical Cancer Research</i> , 2014 , 20, 528-30	12.9
560	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. 2014 , 111, 1888-98	83
559	Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. 2014 , 110, 2647-54	14
558	Successes and limitations of targeted cancer therapy in breast cancer. 2014 , 41, 15-35	23
557	Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). 2014 , 26, 300-5	17
556	Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. 2014 , 19, 135-50	43

555	HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. 2014 , 4, 791-823		
554	Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report. <i>Oncology Letters</i> , 2014 , 8, 2448-2452	2.6	3
553	Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. <i>Annals of Oncology</i> , 2014 , 25, 773-780	10.3	5
552	Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. 2014 , 2014, 168949		17
551	Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. 2014 , 10, 967-72		1
550	Molecular mechanisms regulating the hormone sensitivity of breast cancer. 2014 , 105, 1377-83		24
549	Role of endocrine therapy in ER+/HER2+breast cancers. 2014 , 3, 103-111		2
548	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. 2014 , 4, 19-33		5
547	Clinical experience with ramucirumab : outcomes in breast cancer. 2014 , 14, 1351-60		4
546	mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. 2014 , 10, 443-56		11
545	Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells. 2014 , 14, 107		4
544	Marker Sequential Test (MaST) design. 2014 , 11, 19-27		37
543	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 2014 , 13, 535-49		22
542	Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor positive advanced breast cancer: CALGB 40302 (Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 3959-66	2.2	66
541	Advances in mechanisms of resistance to aromatase inhibitors. 2014 , 14, 381-93		8
540	Lapatinib. 2014 , 201, 125-43		12
539	Hormone Responsive Cancers. 2014 , 651-698.e14		
538	Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 736-43	12.9	23

537	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. 2014 , 10, 21-40	11
536	A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified. 2014 , 24, 19-41	20
535	Adverse events of targeted therapies. 2014 , 26, 395-402	12
534	Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. 2014 , 5, 2-7	5
533	The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. 2014 , 9, 111-22	21
532	Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. 2014 , 32, 481-8	27
531	Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. 2014 , 144, 263-72	43
530	Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. 2014 , 382, 683-694	40
529	Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. 2014 , 15, 407-20	70
528	Small Molecules in Oncology. 2014 ,	3
527	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 2014 , 15, 681-700	40
526	Systemic treatment of HER2-positive metastatic breast cancer: a systematic review. 2014 , 10 Suppl S4, 1-14	8
525	Cardiotoxicity of systemic agents used in breast cancer. 2014 , 23, 317-28	44
524	Biomarkers of drugs targeting HER-family signalling in cancer. 2014 , 232, 219-29	47
523	Breast cancer: current and future endocrine therapies. 2014 , 382, 695-723	69
522	Time for more optimism in metastatic breast cancer?. 2014 , 40, 220-8	44
521	Targeted therapy-induced diarrhea: A review of the literature. 2014 , 90, 165-79	37
520	Biomarker enrichment strategies: matching trial design to biomarker credentials. 2014 , 11, 81-90	121

519	Treatment of HER2-positive breast cancer. 2014 , 23, 128-136		134
518	Tracking progesterone receptor-mediated actions in breast cancer. 2014 , 142, 114-25		51
517	Co-targeting estrogen receptor and HER2 pathways in breast cancer. 2014 , 23, 2-9		25
516	Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. 2014 , 74, 617-27		18
515	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. 2014 , 23, 710-20		31
514	Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1472-9	2.2	26
513	Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3634-42	2.2	52
512	Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1050-7	2.2	40
511	Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice. 2014 , 50, 2303-8		27
510	Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2296-303	2.2	61
509	Targeted therapy in older patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2635-46	2.2	31
508	Therapeutic antibodies in breast cancer. 2014 , 41, 576-88		3
507	Prise en charge du cancer du sein, avancès et perspectives. 2014 , 38, 299-302		
506	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. <i>Annals of Oncology</i> , 2014 , 25, 2357-2362	10.3	361
505	Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. 2014 , 146, 245-58		33
504	Emerging strategies to overcome resistance to endocrine therapy for breast cancer. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 791-807	9.6	15
503	Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. 2014 , 6, 169-182		14
502	Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology. 2014 , 31, 929		4

501	Advances in the approach to novel drug clinical development for breast cancer. 2014 , 9, 647-68		5
500	Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. 2014 , 148, 437-44		29
499	Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action. 2014 , 14, 75-84		24
498	Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. 2014 , 23, 165-9		13
497	Resistance to human epidermal growth factor receptor type 2-targeted therapies. 2014 , 50, 892-901		37
496	Personalized medicine: present and future of breast cancer management. 2014 , 91, 223-33		40
495	T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. 2014 , 344, 90-100		19
494	Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. 2014 , 15, 93-112		19
493	Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. 2014 , 3, 108		1
492	S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. <i>Endocrine-Related Cancer</i> , 2015 , 22, 331-43	5.7	19
491	Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. 2015 , 13, 1066-70		25
490	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. 2015 , 10, 33-40		7
489	Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer. 2015 , 9, 65-73		10
488	Breast carcinoma. 679-690		
487	Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. <i>BMC Cancer</i> , 2015 , 15, 787	4.8	5
486	The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. <i>BMC Cancer</i> , 2015 , 15, 791	4.8	23
485	Palliative systemic therapy for young women with metastatic breast cancer. 2015 , 9, 301-7		4
484	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. 2015 , 7, 125-32		7

483	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. 2015 , e117-25		10
482	Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. 2015 , 6, 575-82		4
481	Optimal management of breast cancer in the elderly patient: current perspectives. 2015 , 10, 157-74		18
480	Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. <i>Cancer Management and Research</i> , 2015 , 7, 37-46	3.6	13
479	Targeting RTK Signaling Pathways in Cancer. <i>Cancers</i> , 2015 , 7, 1758-84	6.6	213
478	Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. 2015 , 10, e0127404		12
477	Molekular stratifizierte Therapie und patientenrelevante Endpunkte. 2015 , 30, 122-126		1
476	A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. 2015 , 15, 101-9		36
475	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. 2015 , 7, 190-202		
474	Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. 2015 , 31, 424-32		1
473	IN03 IS THERE AN OPTIMAL TREATMENT SEQUENCE FOR HER2 POSITIVE ADVANCED BREAST CANCER?. 2015 , 24, S21-S22		
472	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. 2015 , 10, 168-72		19
471	SEOM clinical guidelines in metastatic breast cancer 2015. 2015 , 17, 946-55		23
470	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. 2015 , 17, 140		114
469	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. 2015 , 96, 206-19		20
468	CDK4/6 inhibitors in luminal breast cancer. 2015 , 16, 2-3		5
467	Triple positive breast cancer: a distinct subtype?. 2015 , 41, 69-76		56
466	HER2-directed therapy: current treatment options for HER2-positive breast cancer. 2015 , 22, 101-16		127

465	Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. 2015 , 94, 291-301		19
464	Targeting HER2 for the treatment of breast cancer. 2015 , 66, 111-28		160
463	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1045-52	2.2	97
462	Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). <i>Clinical Cancer Research</i> , 2015 , 21, 2932-40	12.9	21
461	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. 2015 , 16, 402-11		31
460	HER2-positive metastatic breast cancer: a changing scenario. 2015 , 95, 78-87		19
459	Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. 2015 , 22, S19-28		25
458	Clinical Trials Combining Aromatase Inhibitors with Other Targeted Treatments. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 229-259	0.3	
457	De-escalation attempts for adjuvant trastuzumab: longer beats shorter. <i>Annals of Oncology</i> , 2015 , 26, 1275-6	10.3	
456	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. 2015 , 51, 685-96		7
455	Biologisch stratifizierte Therapie. 2015 , 20, 38-44		
454	Resistance to Aromatase Inhibitors in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 ,	0.3	1
453	EPMA position paper in cancer: current overview and future perspectives. 2015 , 6, 9		60
452	Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. 2015 , 1, 324-335		16
451	Incidence and risk of xerosis with targeted anticancer therapies. 2015 , 72, 656-67		30
450	Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). <i>Annals of Oncology</i> , 2015 , 26, 1333-40	10.3	109
449	Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. 2015 , 94, 270-8		4
448	Das metastasierte Mammakarzinom –Medikamentöse Therapie individuell nach Patientin und Tumor. 2015 , 44, 105-110		

447	The changing role of ER in endocrine resistance. 2015 , 24 Suppl 2, S60-6	62
446	Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?. 2015 , 42, e67-79	
445	Better Together: Targeted Combination Therapies in Breast Cancer. 2015 , 42, 887-95	39
444	Optimal management of hormone receptor positive metastatic breast cancer in 2016. 2015 , 7, 304-20	81
443	Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis. 2015 , 31, 975-86	10
442	Individuelle Tumorthherapie beim Mammakarzinom – Möglichkeiten der Vermeidung von Über- und Untertherapie unter besonderer Berücksichtigung zielgerichteter Therapien. 2015 , 47, 57-65	0
441	Endocrine resistance in breast cancer--An overview and update. 2015 , 418 Pt 3, 220-34	200
440	Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. 2015 , 7, 1511-9	73
439	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. 2015 , 107,	65
438	Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. 2015 , 11, 1493-500	8
437	Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 115-144	0.3
436	Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?. <i>Current Oncology Reports</i> , 2015 , 17, 46	6.3 6
435	Renal toxicity of anticancer agents targeting HER2 and EGFR. 2015 , 28, 647-57	28
434	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade. 2015 , 24, 699-704	5
433	Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. 2015 , 24 Suppl 2, S44-8	18
432	A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. 2015 , 220, 189-200	44
431	Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer. 2015 , 11, 281-94	1
430	Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. 2015 , 4, 203-9	0

429	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. 2015 , 16, 25-35	1241
428	Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis. 2015 , 15, 90-100.e1	33
427	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. 2015 , 12, 197-212	139
426	Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?. 2015 , 121, 517-26	18
425	Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?. 2015 , 121, 17-24	7
424	Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells. 2016 , 8, 211-221	4
423	Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors. 2016 , 7, 2165-2172	10
422	Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective. 2016 , 9, 1077-84	4
421	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. 2016 , 35, e40-54	25
420	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. 2016 , 11, e0156221	2
419	Novel Treatments in Breast Cancer. 2016 , 8, CMT.S18492	0
418	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. 2016 , 122, 2961-70	7
417	Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. 2016 , 117, 2454-63	8
416	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. 2016 , 24, 4057-74	12
415	First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. 2016 , 35, 104	29
414	Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. 2016 , 11, 418-422	12
413	Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. 2016 , 14, 324	11
412	Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. 2016 , 12, 583-587	16

411	Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures. 2016 , 104, 42-51		7
410	Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3069-103	2.2	341
409	Tyrosine Kinase Inhibitors. 2016 , 617-631		
408	Targeted Therapy in HER2-Positive Breast Cancer. 2016 , 39, 295-302		4
407	Specialty pharmacy services for patients receiving oral medications for solid tumors. 2016 , 73, 775-96		10
406	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. 2016 , 108,		18
405	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. 2016 , 2, 901-5		31
404	Zielgerichtete Therapie des HER2-positiven metastasierten Mammakarzinoms. 2016 , 13, 26-33		
403	Treatment of HER2-Overexpressing Metastatic Breast Cancer. 2016 , 535-573		
402	Genomic profiling and treatment of HER2+, ER+, PgR+ "triple positive" breast cancer: A case report and literature review. 2016 , 9, 27-31		5
401	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. 2016 , 160, 91-99		22
400	Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. 2016 , 88, 245-251		5
399	Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. 2016 , 37, 15411		25
398	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. 2016 , 40, 117-129		1
397	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. 2016 , 78, 685-95		11
396	Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature. 2016 , 22, 218-23		13
395	Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. 2016 , 12 Suppl 1, 19-31		2
394	Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. 2016 , 44, 1584-97		29

393	Endocrine therapy for hormone treatment-naïve advanced breast cancer. 2016 , 28, 161-6		6
392	Current and emerging therapies of HER2-positive metastatic breast cancer. 2016 , 29, 170-7		19
391	Endocrine treatment in breast cancer: Cure, resistance and beyond. 2016 , 50, 68-81		86
390	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. 2016 , 8, 429-449		25
389	Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. 2016 , 40, 95-105		16
388	Metastatic breast cancer: The Odyssey of personalization. 2016 , 10, 1147-59		15
387	Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. 2016 , 1, e000062		33
386	Twenty years of anti-HER2 therapy-associated cardiotoxicity. 2016 , 1, e000073		49
385	Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance. 2016 , 8, 193-205		2
384	Resistance to Tyrosine Kinase Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 ,	0.3	1
383	Approaches to modernize the combination drug development paradigm. 2016 , 8, 115		42
382	Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons. 2016 , 102, 472-480		8
381	Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. 2016 , 10, 21-30		82
380	Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. 2016 , 11, 133-8		3
379	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. 2016 , 5, 45		12
378	HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. <i>BMC Cancer</i> , 2016 , 16, 352	4.8	93
377	The Role of mTOR Inhibitors in Breast Cancer. 2016 , 67-92		
376	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 936-44	2.2	14

375	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. 2016 , 76, 1615-26	59
374	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. 2016 , 71, 12-23	16
373	Metastatic disease of the breast and local recurrence. 2016 , 34, 47-51	
372	A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. 2016 , 19, 619-29	17
371	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2016 , 27, 1029-1034	27
370	The role of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension. 2016 , 37, 81-4	14
369	Cancer Drug Resistance. 2016 ,	3
368	Targeted therapies in gastric cancer treatment: where we are and where we are going. 2016 , 34, 378-93	14
367	Resistance to Targeted Therapies in Breast Cancer. 2016 , 1395, 105-36	14
366	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. 2016 , 23, 329-42	24
365	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. 2016 , 100, 57-68	13
364	FOXO factors and breast cancer: outfoxing endocrine resistance. <i>Endocrine-Related Cancer</i> , 2016 , 23, R113-30	5-7 34
363	Current challenges in HER2-positive breast cancer. 2016 , 98, 211-21	27
362	Trial watch - inhibiting PARP enzymes for anticancer therapy. 2016 , 3, e1053594	18
361	Nouvelles approches thfapeutiques dans le cancer du sein HER2 positif. 2017 , 19, 108-119	
360	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. 2017 , 165, 228-235	6
359	Defining the optimal sequence for the systemic treatment of metastatic breast cancer. 2017 , 19, 149-161	20
358	Principles of Kinase Inhibitor Therapy for Solid Tumors. 2017 , 265, 311-319	9

357	Antibody Drug and Radionuclide Conjugates for GI Cancers. 2017 , 79-99		1
356	Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease. 2017 , 163, 37-50		12
355	Tyrosine kinase-targeting drugs-associated heart failure. 2017 , 116, 1366-1373		18
354	The prognostic significance of Cdc6 and Cdt1 in breast cancer. 2017 , 7, 985		38
353	Neoadjuvant Trials in ER Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. 2017 , 7, 561-574		22
352	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. 2017 , 79, 863-871		12
351	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. 2017 , 13, 1371-1384		5
350	Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials. 2017 , 36, 1334-1360		32
349	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. 2017 , 19, 54		17
348	EGFR, Immunology. 2017 , 199-208		
347	Addressing the quality of the ESMO-MCBS. <i>Annals of Oncology</i> , 2017 , 28, 1406	10.3	8
346	HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. 2017 , 39, 1010428317695028		8
345	Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells. <i>BMC Cancer</i> , 2017 , 17, 199	4.8	10
344	Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. 2017 , 116, 10-20		11
343	Immunotherapy for Gastrointestinal Cancer. 2017 ,		0
342	Defining what matters most to patients. 2017 , 26, S15-S20		0
341	Current treatment of HER 2+ metastatic breast cancer. 2017 , 26, S7-S14		1
340	Manual of Cardio-oncology. 2017 ,		1

339	Advances in the management of HER2-positive early breast cancer. 2017 , 119, 113-122		31
338	Foreword. 2017 , 26, S3		
337	Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity. 2017 , 8, 552		17
336	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. 2017 , 7, 6882		17
335	Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio. <i>Annals of Oncology</i> , 2017 , 28, 2031-2032	10.3	
334	Erhaltungstherapie bei metastasiertem Mammakarzinom. 2017 , 50, 312-319		
333	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. <i>Oncology Letters</i> , 2017 , 14, 1725-1730	2.6	2
332	Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. 2017 , 15, 220-235		54
331	Resistance to Targeted Therapies in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 ,	0.3	
330	Improving patient care: expert nursing and service development. 2017 , 26, S21-S25		
329	Versorgungsrealität der molekularen Diagnostik maligner Erkrankungen. <i>Onkologe</i> , 2017 , 23, 900-910	0.1	1
328	Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings. 2017 , 577-591		
327	Breast cancer treatment-induced cardiotoxicity. 2017 , 16, 1021-1038		28
326	Treatment for the endocrine resistant breast cancer: Current options and future perspectives. 2017 , 172, 166-175		26
325	Evolution of anti-HER2 therapies for cancer treatment. 2017 , 59, 1-21		52
324	Neratinib for the treatment of HER2-positive early stage breast cancer. 2017 , 17, 669-679		16
323	The role of neratinib in HER2-driven breast cancer. 2017 , 13, 1931-1943		11
322	More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. 2017 , 31, 99-104		13

321	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756		
320	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. 2017 , 22, 12-24		10
319	New Approaches to Investigate Drug-Induced Hypersensitivity. 2017 , 30, 239-259		15
318	Over-treatment in metastatic breast cancer. 2017 , 31, 309-317		16
317	Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. 2017 , 17, 79-90		16
316	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. <i>Clinical Cancer Research</i> , 2017 , 23, 1710-1721	12.9	101
315	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. 2017 , 1026, 403-418		4
314	Targeted Therapies Against Growth Factor Signaling in Breast Cancer. 2017 , 1026, 125-146		5
313	Introduction. 2017 , 26, S4-S6		
312	ERF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. 2017 , 8, 36054-36066		4
311	Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	6
310	Lapatinib. 2017 , 243-264		
309	Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	27
308	Physicochemical Characterization and Cyclodextrin Complexation of the Anticancer Drug Lapatinib. 2017 , 2017, 1-9		9
307	Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. 2017 , 50, 2221-2228		14
306	Targeting protein quality control pathways in breast cancer. 2017 , 15, 109		19
305	Novel Strategies to Improve the Endocrine Therapy of Breast Cancer. 2017 , 11, 323		21
304	Optimal Management of Early and Advanced HER2 Breast Cancer. 2017 , 37, 76-92		11

303	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. 2017 , 13, e653-e665	21
302	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. 2017 , 8, 72281-72301	9
301	Optimising endocrine therapy in postmenopausal women with advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2018 , 25, 705-721	5-7 1
300	HER2-positive breast cancer: Current and new therapeutic strategies. 2018 , 39, 80-88	57
299	Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. 2018 ,	2
298	An update on first line therapies for metastatic breast cancer. 2018 , 19, 243-252	5
297	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). 2018 , 168, 631-638	35
296	HER2-Positive Breast Cancer. 2018 , 763-768.e2	1
295	Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. 2018 , 14, 589-602	5
294	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. 2018 , 579-594	1
293	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. 2018 , 118, 1599-1663	51
292	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. 2018 , 19, 249-256	89
291	A new era for treatment development in HER2-positive breast cancer. 2018 , 19, 160-162	5
290	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. 2018 , 48, 242-247	4
289	Treatment of advanced HER2-positive breast cancer: 2018 and beyond. 2018 , 67, 10-20	77
288	Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. 2018 , 74, 327-338	29
287	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. 2018 , 6, 329-342.e6	36
286	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. 2018 , 170, 329-341	10

285	Risk of Gastrointestinal Events During Lapatinib Therapy: A Meta-Analysis From 12,402 Patients With Cancer. 2018 , 25, e412-e422		
284	The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. 2018 , 119, 213-222		54
283	Patient Case Lessons: Endocrine Management of Advanced Breast Cancer. 2018 , 18, 192-204		7
282	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018 , 24, 701-716	2.6	13
281	Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. 2018 , 20, 862-869		2
280	Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. 2018 , 168, 457-465		5
279	Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. 2018 , 168, 357-364		27
278	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. 2018 , 62, 123-132		14
277	Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. 2018 , 18, 480-486		9
276	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3259-3268	2.2	10
275	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018 , 36, 741-748	2.2	66
274	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2024-2035	2.2	82
273	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. 2018 , 38, 65-77		10
272	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. 2018 , 38, 78-86		20
271	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. 2018 , 24, 494-502		0
270	Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data. 2018 , 21, 415-424		3
269	12 Medical Treatment of Breast Cancer. 2018 ,		
268	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. 2018 , 4, 41		30

267	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. 2018 , 34, 893-905.e8		166
266	Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series. 2018 , 11, 5459-5463		13
265	Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. 2018 , 9, 358-366		6
264	Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. 2018 , 27, 787-801		12
263	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. 2018 , 34, 427-438.e6		339
262	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. 2018 , 37, 3387-3402		5
261	Overcoming endocrine resistance in hormone receptor-positive breast cancer. 2018 , 25, S18-S27		61
260	Lapatinib. 2018 , 211, 19-44		41
259	Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. 2018 , 20, 44		13
258	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2018 , 8, 89	5-3	49
257	Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. 2018 , 16, 38-44		2
256	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. 2018 , 2018, 7835095		12
255	Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. 2018 , 17, 34		101
254	Versorgungsrealität der molekularen Diagnostik maligner Erkrankungen. 2018 , 21, 172-177		
253	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018 , 7, 2442-2451	4.8	8
252	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. 2018 , 67, 63-70		45
251	The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality. 2018 , 18, 480-498		2
250	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. 2018 , 10, 1758835918786858		3

249	Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. <i>Annals of Oncology</i> , 2018 , 29, 1777-1783	10.3	41
248	Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. 2019 , 79, 1849-1866		18
247	Breast Cancer Metastasis and Drug Resistance. 2019 ,		13
246	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. 2019 , 15, 3309-3326		5
245	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. 2019 , 4, 34		125
244	The Use of Immunotherapy to Treat Metastatic Breast Cancer. 2019 , 26, 941-962		9
243	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. 2019 , 19, 188-196		2
242	Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis. 2019 , 59, 935-946		2
241	Effects of carfilzomib alone and in combination with cisplatin on the cell death in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cell lines. 2019 , 120, 468-475		
240	Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. 2019 , 10, 245		75
239	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. 2019 , 177, 237-250		41
238	Cardiotoxicity of Contemporary Breast Cancer Treatments. 2019 , 20, 51		9
237	Synthesis of Quinazoline and Quinazolinone Derivatives via Ligand-Promoted Ruthenium-Catalyzed Dehydrogenative and Deaminative Coupling Reaction of 2-Aminophenyl Ketones and 2-Aminobenzamides with Amines. 2019 , 21, 3337-3341		36
236	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. 2019 , 139, 53-66		68
235	Metastatic disease of the breast and local recurrence. 2019 , 37, 181-185		
234	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 2019 , 10, 1373		137
233	HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. 2019 , 11, 1758835919833519		9
232	Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer. 2019 , 41-62		

231	HER2-Positive Breast Cancer. 2019 , 63-74	1
230	Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Co-expressing Tumors. 2019 , 119-133	
229	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). 2019 , 11, 1758835919891608	2
228	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. 2019 , 1-26	
227	HITTING A MOVING TARGET: 2019 STANDARDS OF CARE AND TREATMENT OPTIMIZATION FOR HER2+ ABC. 2019 , 48, S29-S30	
226	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. 2019 , 11, 1758835919894105	10
225	Overcoming Endocrine Resistance in Breast Cancer: mTOR Inhibitors and New Drugs. 2019 , 393-422	2
224	Estrogen Receptor and Breast Cancer. 2019 ,	3
223	Systemic Treatment of HER2-Overexpressing Metastatic Breast Cancer. 2019 , 509-531	
222	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). 2019 , 21, 31-45	8
221	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. 2019 , 75, 697-706	2
220	Molecular Mechanisms of Endocrine Resistance. 2019 , 265-307	4
219	Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. 2019 , 120, 4180-4191	0
218	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER/HER2 Breast Cancers: Implications to the ExteNET Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 771-783	12.9 18
217	The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients. 2020 , 22, 576-584	7
216	Targeted therapy for breast cancer in older patients. 2020 , 11, 380-388	8
215	Intracellular Signaling. 2020 , 24-46.e12	
214	Cancer of the Breast. 2020 , 1560-1603.e12	6

213	Understanding the benefits and challenges of first-line cyclin-dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women. 2020 , 26, 630-642		3
212	Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. 2020 , 77, 1571-1589		10
211	Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling. 2020 , 29, 101391		14
210	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. 2020 , 179, 687-697		6
209	Towards personalized treatment for early stage HER2-positive breast cancer. 2020 , 17, 233-250		71
208	Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020 , 19, 1533033820962140	2.7	5
207	Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. <i>BMC Cancer</i> , 2020 , 20, 653	4.8	6
206	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020 , 12,	6.6	7
205	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). 2020 , 126 Suppl 16, 3867-3882		6
204	Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. 2020 , 133, 2338-2345		1
203	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). 2020 , 13, 143		61
202	Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020 , 9, 9246-9255	4.8	1
201	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. 2020 , 20, 731-741		1
200	The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. 2020 , 13, 113		71
199	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
198	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020 , 12,	6.6	5
197	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. 2020 , 5,		9
196	Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells. 2020 , 28, 1375-1386		4

195	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. <i>Cancer Medicine</i> , 2020 , 9, 5035-5050	4.8	3
194	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. <i>Clinical Cancer Research</i> , 2020 , 26, 1105-1113	12.9	10
193	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. 2020 , 16, 1165-1177		1
192	Quinazolinone and Quinazoline Derivatives: Synthesis and Biological Application. 2020 ,		1
191	First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. 2020 , 38, 1826-1835		1
190	2. Therapie des metastasierten Mammakarzinoms. 2020 , 71-120		
189	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. 2020 , 88, 102064		20
188	Anti-HER2 therapy for breast cancer in older patients. 2020 , 16, 1393-1407		
187	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. 2020 , 22, 1364-1377		
186	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. 2020 , 180, 135-146		13
185	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. 2020 , 34, 257-270		
184	HER2-positives und metastasiertes Mammakarzinom: Standards und neue Entwicklungen. <i>Onkologe</i> , 2020 , 26, 518-523	0.1	1
183	Overcoming Endocrine Resistance in Breast Cancer. 2020 , 37, 496-513		121
182	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. 2020 , 21, 763-775		69
181	CDK4/6 inhibition in HER2-positive breast cancer. 2020 , 21, 734-735		1
180	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. 2020 , 40, 1-11		4
179	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2021 , 39, 79-89	2.2	22
178	Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). 2021 , 185, 107-116		1

177	Molecular Biology in the Breast Clinics-Current status and future perspectives. 2021 , 12, 7-20		
176	Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study. 2021 , 7, e27073		0
175	HER2 Signaling in Breast Cancer. 2021 , 1187, 53-79		2
174	Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer. 2021 , 13, 17588359211013326		3
173	Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. 2021 , 7, 11		6
172	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. <i>Frontiers in Oncology</i> , 2020 , 10, 599604	5.3	2
171	The changing treatment of metastatic her2-positive breast cancer. <i>Oncology Letters</i> , 2021 , 21, 287	2.6	2
170	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. 2021 , 21, e575-e583		4
169	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	7
168	HER2-zielgerichtete Therapien â€”mehr als nur Antikâ€œper. 2021 , 54, 320-328		
167	Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings. <i>Indian Journal of Medical and Paediatric Oncology</i> , 42,	0.2	
166	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. 2021 , 7, 56		24
165	Current trends in the treatment of HR+/HER2+ breast cancer. 2021 , 17, 1665-1681		4
164	Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. 2021 , 13, 361-381		0
163	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2128-2137	2.2	4
162	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. 2021 , 7, 80		2
161	Mechanisms of endocrine therapy resistance in breast cancer. 2021 , 532, 111322		5
160	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. 2021 , 189, 15-23		2

159	HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer. 2021 , 162,		2
158	A Problematic Biomarker Trial Design. 2021 ,		2
157	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). 2021 , 190, 103-109		0
156	Breast Cancer Treatments: Updates and New Challenges. 2021 , 11,		16
155	Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report. 2021 , 9, 1356		0
154	The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. 2021 , 154, 175-189		5
153	Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. 2021 , 13, 539-557		0
152	MLL3 is a de novo cause of endocrine therapy resistance. <i>Cancer Medicine</i> , 2021 , 10, 7692-7711	4.8	1
151	Anti-HER2 antibody prolongs overall survival disproportionately more than progression-free survival in HER2-Positive metastatic breast cancer patients. 2021 , 59, 211-220		0
150	Suggested modifications in the management of breast cancer patients in the era of COVID-19 pandemic: a web-based survey. (Preprint).		
149	Breast Cancer. 2013 , 29-117		1
148	Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer. 2013 , 179-210		1
147	Resistance to Endocrine Therapy in Breast Cancer: Are Breast Cancer Stem Cells Implicated?. 2011 , 381-402		1
146	Therapeutic Options for Metastatic Breast Cancer. 2019 , 1152, 131-172		14
145	Data-Driven and Confirmatory Subgroup Analysis in Clinical Trials. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020 , 33-91	0.2	3
144	Resistance to HER2-Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 35-88	0.3	2
143	Breast Cancer. 2018 , 21-84		1
142	Cancer of the Breast. 2014 , 1630-1692.e9		1

141	HER2-positive advanced breast cancer treatment in 2020. 2020 , 88, 102033		30
140	New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies. 2017 , 29, 405-410		5
139	The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. 2015 , 10, e0130928		9
138	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. 2015 , 10, e0133219		16
137	Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Applying the Results from Recent Clinical Trials into Daily Practice—Insights, Limitations, and Moving Forward. 2013 , e20-e27		2
136	Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents. 2013 , e28-e36		3
135	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. 2020 , 25, e130-e137		12
134	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. 2015 , 6, 17738-52		13
133	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. 2016 , 7, 64431-64446	113	
132	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. 2016 , 7, 17932-44		26
131	Detection of Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. <i>Frontiers in Oncology</i> , 2020 , 10, 587671	5-3	4
130	Hormone Therapy for Metastatic Breast Cancer. <i>Korean Journal of Medicine</i> , 2017 , 92, 251-258	0.5	1
129	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. 2015 , 3, 242		12
128	Newer therapies for the treatment of metastatic breast cancer: a clinical update. 2013 , 75, 251-61		14
127	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. 2019 , 51, 1527-1539		2
126	Lapatinib, a TKI Dual Inhibitor of Her1 and Her2 Receptors: Review of the Literature. 2012 , 03, 1132-1139		1
125	Genetically Targeted Fractionated Chemotherapy. 2015 , 06, 182-198		4
124	New Oncological Drugs: Analysis of Survival Gain. 2014 , 1, GRHTA.2014.1235		4

123	Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. 2014 , 5, 248-62		40
122	Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. 2010 , 154, 281-8		16
121	Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. 2019 , 163, 285-292		3
120	Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. 2011 , 30, 327-35		28
119	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. 2011 , 30, 5-12		86
118	Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014 , 5, 246-60	0.7	9
117	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 , 18, 452-478		283
116	Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. 2014 , 15, 3185-9		4
115	Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China. 2015 , 16, 903-7		2
114	Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. <i>Cancers</i> , 2021 , 13,	6.6	3
113	Stratgies thrapeutiques des cancers mfastatiques RH+, HER2+ : trastuzumab, chimiothrapie, hormonothrapie. 2010 , 207-221		
112	Chimiothrapie du cancer du sein mfastatique RH ngatif HER2 positif. 2010 , 223-232		
111	Hormonothrapie des cancers du sein. 2011 , 47-53		
110	Traitements systmiques des cancers du sein mfastatiques. 2011 , 185-196		
109	Endocrine therapy for advanced disease. 2011 , 13-34		
108	Targeting HER2+and trastuzumab-resistant metastatic breast cancer. 2011 , 035-049		
107	Present and Emerging Targeted Therapy for Metastatic Breast Cancer.		
106	Comment augmenter la performance des mdicaments anti-HER?. 2012 , 529-551		

105 Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications. **2012**, 553-564

104 Inflammatory Breast Cancer: Chemotherapy of Metastatic Disease. **2012**, 101-120

103 Veille bibliographique cancer du sein méta-analyse en première ligne. Mise à jour des traitements en première ligne métastatique. **2012**, 77-102

102 Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs. **2012**, 499-528

101 Breast Cancer. **2012**, 195-219

100 Follow-Up in Inflammatory Breast Cancer. **2013**, 129-139

99 EGFR, Immunology. **2013**, 1-10

98 HER2-Positive Metastatic Breast Cancer: First-Line Treatment. **2013**, 43-60

97 Breast Cancer. 241-267

96 Mammakarzinom. **2013**, 625-705

95 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50

94 HER2 Inhibition and Clinical Achievements. **2013**, 51-80

93 Endocrine Agents. 248-256

92 Systemic Treatment of Older Patients with Advanced Breast Cancer. *Korean Journal of Medicine*, **2014**, 87, 542 0.5

91 Intracellular Signaling. **2014**, 22-39.e8

90 EGF receptor inhibitors: patient selection and clinical outcomes. **2014**, 68-78

89 Management of Metastatic Breast Cancer. **2015**, 473-497

88 Adjuvant Biologic Agents for Breast Cancer. **2015**, 363-375

87	In Vivo Models of AI Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 63-86	0.3
86	Targeted Therapies for HER2-positive Breast Cancer. <i>Current Clinical Pathology</i> , 2015 , 57-72	0.1
85	Pharmacology and Clinical Development of New Molecularly Targeted Agents. <i>Current Clinical Pathology</i> , 2015 , 9-29	0.1
84	A Case of Locally Advanced HER2-positive Breast Cancer in Complete Remission for a Long Period. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2015 , 76, 16-20	0
83	HER2-positive metastatic breast cancer: first-line treatment. 2016 , 51-69	
82	Treatment of Metastatic Breast Cancer: Endocrine Therapy. 2016 , 489-522	
81	Metastatic Breast Cancer. 2016 , 451-474	
80	Systemic Therapy. 2016 , 335-390	
79	Endocrine Therapy. 2016 , 323-334	
78	Human Epidermal Growth Factor Receptor 2 (HER2): Translating the Lab to the Clinic. 2016 , 59-70	
77	Molecular Classification of Breast Cancer. 2016 , 203-219	0
76	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 , 179-188	0.3
75	Challenges of Endocrine Therapy in Breast Cancer. 2017 , 825-850	
74	Cardiotoxicity in Long-Term Survivors. 2017 , 291-308	
73	Systemic Treatment for Specific Medical Situations. 2017 , 599-607	
72	Trial Designs and Biostatistics for Molecular-Targeted Agents. 2017 , 915-924	
71	Receptor Tyrosine Kinases in Human Platelets: A Review of Expression, Function and Inhibition in Relation to the Risk of Bleeding or Thrombocytopenia from Phase I through Phase III Trials. <i>Journal of Cancer Prevention & Current Research</i> , 2017 , 8,	1.3 0
70	Endocrine Therapy of Metastatic Breast Cancer. 2019 , 533-555	

69	Treatment of Metastatic Breast Cancer: Endocrine Therapy. 2019 , 419-447		
68	Treatment of HER2-Overexpressing Metastatic Breast Cancer. 2019 , 463-494		
67	Tyrosine Kinase Inhibitors. 2019 , 529-539		
66	Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1.		
65	U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
64	Biomarker-Targeted Confirmatory Trials. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020 , 19-31	0.2	
63	Encyclopedia of Gerontology and Population Aging. 2020 , 1-8		
62	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 1475-1495	10.3	59
61	Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. <i>Cancer Management and Research</i> , 2010 , 2, 13-25	3.6	15
60	Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting. <i>Gland Surgery</i> , 2014 , 3, 81-4	2.2	2
59	Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014 , 5, 321-30	0.7	10
58	Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. <i>American Journal of Cancer Research</i> , 2015 , 5, 2531-61	4.4	46
57	New Agents for the Management of Advanced HER2-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016 , 7, 295-298	0.7	
56	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018 , 9, 43-54	0.7	5
55	Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. <i>American Journal of Cancer Research</i> , 2019 , 9, 2103-2119	4.4	31
54	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020 , 20, 378	2.6	1
53	How We Treat HER2-Positive Metastatic Breast Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021 , 42, 370-375	0.2	
52	I/CuCl-Copromoted Formal [4 + 1 + 1] Cyclization of Methyl Ketones, 2-Aminobenzonitriles, and Ammonium Acetate: Direct Access to 2-Acyl-4-aminoquinazolines. <i>Journal of Organic Chemistry</i> , 2021 , 86, 16916-16925	4.2	1

51	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 766248	5.3	2
50	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. <i>Cancers</i> , 2021 , 13,	6.6	1
49	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002). <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
48	Tyrosine kinase inhibitors in breast cancer (Review).. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 114	2.1	4
47	Therapiealgorithmen für das Mammakarzinom. <i>Onkologe</i> , 2021 , 27, 1165-1174	0.1	
46	Tumors: Breast. 2021 , 5215-5222		
45	N ^N O hydrazone capped pincer type palladium complex catalysed construction of quinazolinones from alcohols. <i>Inorganic Chemistry Communication</i> , 2022 , 137, 109190	3.1	1
44	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020 , 20, 1-1	2.6	0
43	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.. <i>Wiener Klinische Wochenschrift</i> , 2022 , 134, 63	2.3	0
42	Alteration in major cell signaling pathways in cancer. 2022 , 159-186		
41	Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.. <i>BMC Cancer</i> , 2022 , 22, 36	4.8	
40	Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.. <i>Cancer and Metastasis Reviews</i> , 2022 , 41, 193	9.6	1
39	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.. <i>Current Oncology Reports</i> , 2022 , 24, 475	6.3	0
38	Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 775081	5.3	0
37	Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	0
36	Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.. <i>Technology in Cancer Research and Treatment</i> , 2022 , 21, 1533033822109035 ¹	2.7	
35	Breast Cancer. 2022 , 151-192		
34	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022 , 14, 2470	6.6	0

33	Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer. <i>Endocrine-Related Cancer</i> , 2022 ,	5.7	0
32	Contemporary breast cancer treatment-associated thrombosis. <i>Thrombosis Research</i> , 2022 , 213, S8-S15	8.2	
31	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 28 ,	2.6	0
30	Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 7079	6.3	1
29	Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study. <i>Cancer Medicine</i> ,	4.8	0
28	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. 2022 ,		
27	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. 2022 , 14, 3996		2
26	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. 12 ,		
25	Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study. 13 ,		0
24	Targeted therapy for breast cancer: An overview of drug classes and outcomes. 2022 , 204, 115209		2
23	A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ER α -positive luminal breast cancer. 2022 , 204, 115233		0
22	Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. 2022 , 14, 175883592211136		1
21	Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.		0
20	The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. 2022 , 39,		0
19	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. 2022 , 14, 4543		2
18	Small molecule inhibitors targeting the cancers. 2022 , 3,		0
17	Letrozole: Pharmacology, toxicity and potential therapeutic effects. 2022 , 310, 121074		0
16	Targeting HER2-positive breast cancer: advances and future directions.		3

- 15 Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. **2023**, 112, 102496 ○
- 14 Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. **2023**, 37, 103-115 ○
- 13 Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. **2022**, 14, 6100 ○
- 12 Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review. 12, ○
- 11 Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. ○
- 10 Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. **2023**, 8, 101214 ○
- 9 HER Receptor, Current, and Emerging Therapeutic Targets. **2023**, 1-32 ○
- 8 HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. Volume 16, 115-132 ○
- 7 Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. **2023**, 115, 102527 ○
- 6 Optimizing treatment for HER2-positive HR-positive breast cancer. **2023**, 115, 102529 ○
- 5 Transition-metal-catalyzed synthesis of quinazolines: A review. 11, ○
- 4 Computational Methods Summarizing Mutational Patterns in Cancer: Promise and Limitations for Clinical Applications. **2023**, 15, 1958 ○
- 3 Mecanismos de resistencia al trastuzumab. **2023**, 17, ○
- 2 Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. **2023**, 8, 101216 ○
- 1 SEOMâ€¢EICAMâ€¢SOLTI clinical guidelines in advanced breast cancer (2022). ○